Cargando…

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study

BACKGROUND: Respiratory syncytial virus (RSV) is a significant cause of severe lower respiratory tract disease in children and older adults, but has no approved vaccine. This study assessed the potential of Ad26.RSV.preF to protect against RSV infection and disease in an RSV human challenge model. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sadoff, Jerald, De Paepe, Els, DeVincenzo, John, Gymnopoulou, Efi, Menten, Joris, Murray, Bryan, Rosemary Bastian, Arangassery, Vandebosch, An, Haazen, Wouter, Noulin, Nicolas, Comeaux, Christy, Heijnen, Esther, Eze, Kingsley, Gilbert, Anthony, Lambkin-Williams, Rob, Schuitemaker, Hanneke, Callendret, Benoit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417128/ https://www.ncbi.nlm.nih.gov/pubmed/33400792 http://dx.doi.org/10.1093/infdis/jiab003

Ejemplares similares

902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
por: DeVincenzo, John, et al.
Publicado: (2019)

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
por: Comeaux, Christy, et al.
Publicado: (2019)

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
por: Falsey, Ann R, et al.
Publicado: (2021)

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level
por: Comeaux, Christy A, et al.
Publicado: (2022)

Phase 2b Study of an Ad26.RSV.preF Vaccine for Prevention of RSV-mediated Respiratory Tract Disease in Older Adults
por: Falsey, Ann, et al.
Publicado: (2021)

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
por: Bartsch, Yannic C., et al.
Publicado: (2023)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
por: Saeland, Eirikur, et al.
Publicado: (2023)

Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores
por: Osborne, Richard H., et al.
Publicado: (2023)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis
por: Pickles, Raymond J, et al.
Publicado: (2015)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries
por: Nguyen-Van-Tam, Jonathan S., et al.
Publicado: (2022)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

1941. Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine With Influenza Vaccine in Older Adults
por: Baber, James A, et al.
Publicado: (2023)

Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
por: Bouzya, Badiaa, et al.
Publicado: (2023)

LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
por: Coakley, Eoin, et al.
Publicado: (2019)

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
por: Schwarz, Tino F, et al.
Publicado: (2022)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
por: Fullen, Daniel J., et al.
Publicado: (2016)

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
por: Fullen, Daniel J., et al.
Publicado: (2016)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study
por: Levene, Rachel E, et al.
Publicado: (2023)

A COVID‐19 human viral challenge model. Learning from experience
por: Lambkin‐Williams, Rob, et al.
Publicado: (2020)

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial
por: Bebia, Zourab, et al.
Publicado: (2023)

91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization
por: Simões, Eric A F, et al.
Publicado: (2022)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics
por: Lambkin-Williams, Rob, et al.
Publicado: (2018)

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
por: Krarup, Anders, et al.
Publicado: (2015)

Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Update
por: Krilov, Leonard R., et al.
Publicado: (2022)

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
por: Chee, Chris, et al.
Publicado: (2010)

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
por: Pamela Griffin, Mary, et al.
Publicado: (2019)

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023)

Correction: Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B
por: Hause, Anne M., et al.
Publicado: (2017)

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein
por: DeVincenzo, John, et al.
Publicado: (2020)

Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV
por: Derscheid, Rachel J., et al.
Publicado: (2013)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3k8ntimapt7i4ucq65kgebp30k